ZHAOKE OPHTHALMOLOGY LIMITED SUCCESSFULLY LISTED ON HKEX
Latest Update:
29 th April, 2021

On April 29, 2021, Zhaoke Ophthalmology Limited(" Zhaoke Ophthalmology "or the" Company "; Stock code: 6622) on the main board of the Stock Exchange of Hong Kong Limited (" HKEX ").

Public Offering The initial offer of shares for the public offering was moderately oversubscribed, representing approximately 56 times more than the total number of 12,357,000 shares available for the public offering. The initial offer for the international Placing was also moderately oversubscribed, representing approximately 5.3 times more than the initial 111,210,500 shares available for the International Placing. At the same time, pursuant to the Cornerstone Investment Agreement entered into between the Company and the Cornerstone Investors, the Cornerstone Investors have subscribed for 25,461,000 shares, representing approximately 20.60% of the number of offered shares in the global offering (assuming that the overallotment option is not exercised). For further details on cornerstone investors, please refer to the "Cornerstone Investors" section of the Prospectus.

The final offering shares of Zhaoke Ophthalmology were priced at HK $16.80 per share and the Company expects to receive approximately HK $1,941.6 million in net proceeds from the global offering (after deducting underwriting commissions and other listing related expenses paid or payable by the Company and before any overallotment rights are exercised). The proceeds will be used primarily to fund clinical development and commercialization of core products, to fund ongoing r&d activities and commercialization of other drug candidates in development, to fund production line expansion of the advanced manufacturing facility in Nansha, and to fund business development activities and expansion of drugs in development.

Goldman Sachs (Asia) LIMITED and Furey Financial Group Hong Kong Limited are the joint sponsors, joint representatives, joint global coordinators, joint bookrunners and joint lead managers.

Dr. Xiaoyi Li, Chairman of the Board, Executive Director and CEO of Zhaoke Ophthalmology , said: "Today is a milestone in the development of the company, is officially listed on the stock exchange for our high reputation in the past research achievements and future prospects for development, and further speed up the development of savings for the company. At the same time, set foot on the stage of international capital, will be more conducive to deepening our ophthalmic drug pipeline clinical development and commercial products, promote the competitiveness of the company's industry. We are very honored to receive the support and love of the majority of investors. Future, signs in the eye is committed to the most of our research and development capabilities, and lee's strong base (stock code: 0950) global pharmaceutical support network resources, strengthen and expand the drug pipeline, to establish a high quality sales and marketing network, create brand value, raise awareness, promote the long-term development of the business, and thus big returns for shareholders. We are confident about the company's future growth."

Latest Update:
29 th April, 2021